Clinical trial registry record

Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions

A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 4 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated March 23, 2010.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT00324116
Last registry update
March 23, 2010
Status
Completed
Phase
Phase 4
Sponsor
Pfizer
Enrollment
81
Countries
France
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 4
Study design
NON RANDOMIZED · SINGLE GROUP · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
81
Population
ALL · 50 Years
Duration
2006-07-01 to 2008-08-01
Intervention
pegaptanib sodium (Macugen)
Comparator
Not reported
Outcomes measured
Number of Responders for Visual Acuity Using Early Treatment Diabetic Retinopathy Study (ETDRS) — Baseline, 54 Weeks; Change From Baseline in Visual Acuity — Baseline, 6 weeks, 12 weeks, 54 weeks; Number of Subjects Gaining Vision — 54 weeks or at early termination; Number of Subjects Maintaining Vision — 54 weeks or at early termination; Number of Subjects With Severe Visual Loss — 54 weeks or at early termination; Number of Subjects With a Distance Visual Acuity of > 20/200 at Baseline and Progressing to (<= 20/200) — 54 weeks; Change in Vision-related Functioning and Quality of Life Using the National Eye Institute Visual Functioning Questionna…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 4A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Title supplies ageing or longevity context.

Automated source check 100% · update recency 35%. These figures help sort records; they are not medical ratings.

vision aging
Read the original source →Export JSON